Advertisement

Der Onkologe

, Volume 25, Issue 3, pp 240–245 | Cite as

Primäre und adjuvante Radio(chemo)therapie bei Kopf-Hals-Tumoren

Indikationen, Techniken, Ergebnisse
  • Carmen StrombergerEmail author
Leitthema
  • 26 Downloads

Zusammenfassung

Hintergrund

Die perkutane definitive bzw. adjuvante Radiotherapie oder Radio(chemo)therapie bildet eine der kurativen Behandlungsoptionen beim Plattenepithelkarzinom der Kopf-Hals-Region.

Ziel

Der Beitrag soll eine Übersicht zu aktuell gültigen Behandlungsansätzen und Ergebnissen der Radio(chemo)therapie im Rahmen der definitiven und postoperativen Therapie sein.

Material und Methoden

Es erfolgte eine Sichtung der aktuellen Leitlinien und Literaturrecherche via PubMed-Datenbank.

Ergebnisse

Plattenepithelkarzinom der Kopf-Hals-Region werden stadienadaptiert behandelt. Frühstadien (cT1–2, cN0–1) mit alleiniger Radiotherapie (RT), lokal fortgeschrittenen Stadien mit Radiochemotherapie (RCT). Intensitätsmodulierte RT (IMRT) führt zu vergleichbaren Ergebnissen bei weniger Nebenwirkungen. Partikeltherapie kann Vorteile haben. Die definitive RCT ist der Goldstandard. Adjuvante RT ist bei ≥pT3, pN+, adjuvante RCT bei positivem Resektionsrand oder extranodulärer Ausbreitung (ENE) indiziert. HPV-positive Oropharynxkarzinome haben die beste Prognose. Klinische Studien zur Deintensivierung und Kombination mit Checkpointinhibitoren laufen.

Schlussfolgerung

Moderne perkutane Radiotherapie ist integraler Bestandteil der Therapie, kann Nebenwirkungen reduzieren und wird stadienabhängig alleine oder in Kombination mit Systemtherapie und/oder Operation angewandt. Die Therapie des HPV-assoziierten Oropharynxkarzinoms und HPV-negativen Kopf-Hals-Tumor unterscheidet sich derzeit nicht. Goldstandard im lokal-fortgeschrittenen Stadium ist die simultane Radiochemotherapie mit Cisplatin.

Schlüsselwörter

Humanes Papillomavirus Plattenepithelkarzinom Kopf-Hals-Region Radiotherapie Radiochemotherapie IMRT 

Primary and adjuvant radio(chemo)therapy of head and neck cancer

Indications, techniques, results

Abstract

Background

Percutaneous definitive or adjuvant radiotherapy or radio(chemo)therapy is one of the curative treatment options for squamous cell carcinoma of the head and neck region (HNSCC).

Objective

This article gives an overview of current treatment approaches and results of radio(chemo)therapy in the context of definitive and postoperative treatment.

Material and methods

A review of current guidelines and a literature search via the PubMed database were carried out.

Results

The HNSCC is treated in a stage-adapted manner. Early stages (cT1–2, cN0–1) are treated with radiotherapy alone (RT) and locally advanced stages with radiochemotherapy (RCT). Intensity-modulated RT (IMRT) results in comparable results with fewer side effects. Particle therapy can have advantages. The definitive RCT represents the gold standard. Adjuvant RT is indicated in cases of ≥pT3, pN + and adjuvant RCT for high-risk features such as positive resection margins or extranodal spread (ENE). The HPV positive oropharyngeal carcinomas have the most favorable prognosis. Clinical trials for de-intensification and combination with checkpoint inhibitors are currently recruiting.

Conclusion

Modern percutaneous radiotherapy is an integral part of treatment, can reduce side effects and is used in a stage-dependent manner alone or in combination with systemic treatment and/or surgery. The treatment for HPV-associated and HPV negative HNSCC is identical. The gold standard for locally advanced stages is simultaneous radiochemotherapy with cisplatin.

Keywords

Human papillomavirus Squamous cell carcinoma of the head and neck region Radiotherapy Chemoradiotherapy IMRT 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

C. Stromberger gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
  2. 2.
    Pignon JP, Le Maitre A, Maillard E et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14CrossRefGoogle Scholar
  3. 3.
    Machtay M, Moughan J, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26:3582–3589CrossRefGoogle Scholar
  4. 4.
    Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35CrossRefGoogle Scholar
  5. 5.
    O’sullivan B, Huang SH, Su J et al (2016) Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 17:440–451CrossRefGoogle Scholar
  6. 6.
    Lydiatt WM, Patel SG, O’sullivan B et al (2017) Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. Ca Cancer J Clin 67:122–137CrossRefGoogle Scholar
  7. 7.
    Cramer JD, Hicks KE, Rademaker AW et al (2018) Validation of the eighth edition American Joint Committee on Cancer staging system for human papillomavirus-associated oropharyngeal cancer. Head Neck 40:457–466CrossRefGoogle Scholar
  8. 8.
    Deschuymer S, Mehanna H, Nuyts S (2018) Toxicity reduction in the treatment of HPV positive Oropharyngeal cancer: emerging combined modality approaches. Front Oncol 8:439CrossRefGoogle Scholar
  9. 9.
    Forster MD, Devlin MJ (2018) Immune checkpoint inhibition in head and neck cancer. Front Oncol 8:310CrossRefGoogle Scholar
  10. 10.
    Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5‑year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28CrossRefGoogle Scholar
  11. 11.
    Budach W, Hehr T, Budach V et al (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6:28CrossRefGoogle Scholar
  12. 12.
    Gupta T, Kannan S, Ghosh-Laskar S et al (2015) Concomitant chemoradiotherapy versus altered fractionation radiotherapy in the radiotherapeutic management of locoregionally advanced head and neck squamous cell carcinoma: An adjusted indirect comparison meta-analysis. Head Neck 37:670–676CrossRefGoogle Scholar
  13. 13.
    Cooper JS, Zhang Q, Pajak TF et al (2012) Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 84:1198–1205CrossRefGoogle Scholar
  14. 14.
    Bernier J, Cooper JS, Pajak TF et al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27:843–850CrossRefGoogle Scholar
  15. 15.
    Awmf (2012) Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, 18 AWMF): Diagnostik und Therapie des Mundhöhlenkarzinoms, Langversion 0.2 – 12.2012, AWMF-Registernummer: 007-100OL. https://www.leitlinienprogrammonkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Mundhoehlenkarzinom/S3-Mundhoehlenkarzinom-OL-Langversion_.pdf. Zugegriffen: 6. Nov. 2018Google Scholar
  16. 16.
    Awmf (2018) Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, 18 AWMF): Diagnostik, Therapie und Nachsorge des Larynxkarzinoms, Langversion 0.1 – 19 Juni 2018, AWMF-Registernummer: 017/076OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/larynxkarzinom/. Zugegriffen: 6. Nov. 2018Google Scholar
  17. 17.
    Marta GN, Silva V, De Andrade Carvalho H et al (2014) Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis. Radiother Oncol 110:9–15CrossRefGoogle Scholar
  18. 18.
    Dogan N, King S, Emami B et al (2003) Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing. Int J Radiat Oncol Biol Phys 57:1480–1491CrossRefGoogle Scholar
  19. 19.
    Kim JK, Leeman JE, Riaz N et al (2018) Proton therapy for head and neck cancer. Curr Treat Options Oncol 19:28CrossRefGoogle Scholar
  20. 20.
    Langendijk JA, Boersma LJ, Rasch CRN et al (2018) Clinical trial strategies to compare protons with photons. Semin Radiat Oncol 28:79–87CrossRefGoogle Scholar
  21. 21.
    Brouwer CL, Steenbakkers RJ, Bourhis J et al (2015) CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiother Oncol 117:83–90CrossRefGoogle Scholar
  22. 22.
    Lee AW, Ng WT, Pan JJ et al (2018) International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiotherapy and oncology : journal of the European Society for Therapeutic. Radiol Oncol 126:25–36CrossRefGoogle Scholar
  23. 23.
    Gregoire V, Evans M, Le QT et al (2018) Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol 126:3–24CrossRefGoogle Scholar
  24. 24.
    Gregoire V, Ang K, Budach W et al (2014) Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol 110:172–181CrossRefGoogle Scholar
  25. 25.
    Lacas B, Bourhis J, Overgaard J et al (2017) Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol 18:1221–1237CrossRefGoogle Scholar
  26. 26.
    Budach W, Bolke E, Kammers K et al (2016) Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. Radiother Oncol 118:238–243CrossRefGoogle Scholar
  27. 27.
    Gregoire V, Lefebvre JL, Licitra L et al (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v184–v186CrossRefGoogle Scholar
  28. 28.
    Szturz P, Wouters K, Kiyota N et al (2018) Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis. Oral Oncol 76:52–60CrossRefGoogle Scholar
  29. 29.
    Mehanna H, Robinson M, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 393(10166):51–60.  https://doi.org/10.1016/S0140-6736(18)32752-1. Epub Nov. 15CrossRefGoogle Scholar
  30. 30.
    Gillison ML, Trotti AM, et al. Radiotherapy plus cetuximab or cisplatin human papillomavirus-positive oropharyngeale cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trail. Lancet 393(10166):40–50.  https://doi.org/10.1016/S0140-6736(18)32779-X. Epub 2018 Nov. 15CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Radioonkologie und StrahlentherapieCharité – Universitätsmedizin Berlin, Campus Virchow-KlinikumBerlinDeutschland

Personalised recommendations